Syncona: Kenneth Galbraith

Syncona Ltd. Has announced the appointment of Kenneth Galbraith as Executive in Residence.

Ken brings over 30 years of experience in biotechnology and venture capital and will support Syncona’s portfolio companies as they scale and develop.

Ken has worked as a life sciences executive, director, investor and advisor across North America in the growth of both private and NASDAQ-listed companies from an early-stage through commercialisation.

He began his career in 1987 as Chief Financial Officer at QLT, Canada’s first biotechnology company, where he was instrumental in growing the company to over 500 employees, gaining market approvals for several new medicines and achieving peak market capitalisation of $5bn at the time of his departure in 2000.

Ken also has almost a decade of experience in the management of venture capital funds and new company formation. During his career, he has played a pivotal role in the development of many successful biotechnology companies, including AnorMED where, as Executive Chair, he steered the company to a $584m buyout by Genzyme. Ken has also worked with Macrogenics (MGNX), Alder Pharmaceuticals (sold to Lundbeck), Celator Pharmaceuticals (sold to Jazz Pharma), Novadaq (sold to Stryker), Profound Medical (PROF), Fairhaven Pharmaceuticals (sold to Liminal Bio), Tekmira (merged with OnCore), Angiotech (ANPI), and Aquinox (AQXP) among others.

As a FTSE 250 healthcare company, Syncona’s portfolio of businesses includes gene therapy, cell therapy, small molecule and biologics.